Highbridge Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Highbridge Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$177	Hold	65	–	–	﹤0.01%	426
2026 Q1	$248	Hold	65	–	–	﹤0.01%	369
2025 Q4	$1.22K	Hold	65	–	–	﹤0.01%	289
2025 Q3	$1.58K	Hold	65	–	–	﹤0.01%	285
2025 Q2	$2.88K	Hold	65	–	–	﹤0.01%	278
2025 Q1	$7.08K	Hold	65	–	–	﹤0.01%	235
2024 Q4	$14.4K	Buy	65 +32	+97%	+$9.6K	﹤0.01%	285
2024 Q3	$7.13K	Hold	33	–	–	﹤0.01%	318
2024 Q2	$12.5K	Buy	+33	New	+$16.9K	﹤0.01%	301
2023 Q4	–	Sell	-65	Closed	-$416K	–	364
2023 Q3	$416K	Hold	65	–	–	0.02%	148
2023 Q2	$1.31M	Hold	65	–	–	0.06%	121
2023 Q1	$1.28M	Hold	65	–	–	0.05%	146
2022 Q4	$1.27M	Hold	65	–	–	0.04%	231
2022 Q3	$1.23M	Hold	65	–	–	0.02%	336
2022 Q2	$1.24M	Sell	65 -226	-78%	-$4.31M	0.03%	335
2022 Q1	$5.53M	Sell	291 -534	-65%	-$10.1M	0.13%	228
2021 Q4	$15.5M	Buy	+825	New	+$15.6M	0.34%	94

Other funds holding CLDI

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Highbridge Capital Management's CLDI Position: Q2 2026 in Review

Highbridge Capital Management held its Calidi Biotherapeutics (CLDI) position steady in Q2 2026 at 65 shares worth $177. The position accounts for ﹤0.01% of the portfolio, ranked #426.

Highbridge Capital Management first reported a position in CLDI in Q4 2021 and has held it in 17 quarters since. The position peaked at $15.5M in Q4 2021. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

Highbridge Capital Management held 65 shares of Calidi Biotherapeutics worth $177 as of Q2 2026.
Highbridge Capital Management left its Calidi Biotherapeutics share count unchanged in Q2 2026.
Calidi Biotherapeutics made up ﹤0.01% of Highbridge Capital Management's portfolio in Q2 2026, its #426 holding.
Highbridge Capital Management first reported a position in Calidi Biotherapeutics in Q4 2021 and has held it in 17 quarters since.
Highbridge Capital Management's Calidi Biotherapeutics position peaked at $15.5M in Q4 2021.
22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Highbridge Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.